On October 22, 2020 Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, reported the presentation of new data on the company’s novel hematopoietic progenitor kinase 1 (HPK1) inhibitors at upcoming scientific conferences (Press release, Nimbus Therapeutics, OCT 22, 2020, View Source [SID1234568805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the 32nd EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium, from October 24-25, 2020, Nimbus will present new in vivo data, including target engagement, tumor growth inhibition, and pharmacodynamics in two mouse syngeneic tumor models (CT26 and B16/F10).

Further, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting, from November 9-14, 2020, Nimbus will present new data on in vitro pharmacology and mechanism of action of the HPK1 inhibitors, including effects on T cells, B cells, dendritic cells and antigen presentation.

"Building on the data we presented at AACR (Free AACR Whitepaper) earlier this year, we’re pleased to share these new results which provide further support for the anti-tumor immune activity of our small-molecule HPK1 inhibitors," said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. "We are progressing towards initiation of IND-enabling studies in the near future, with plans to embark upon first-in-human studies of this novel therapeutic in 2021."

Details of the presentations are as follows:

EORTC 2020: Pre-recorded presentation with live Q&A

Title: "A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model"
Presentation Number: PD-046
Date & Time: Sun., Oct. 25, 2:50 p.m. CET (9:50 a.m. ET)
SITC 2020: Live presentation

Title: "A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model"
Poster Number: 685
Dates & Times: Weds., Nov. 11, 5:15 p.m. ET; Fri., Nov. 13, 4:40 p.m. ET